United States · Wires & real time · PR Newswire

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Published by PR Newswire · United States 6 h ago

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Associated Press (Business)

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Business Wire

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

Dow Jones Newswires

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Share

Also worth reading

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

How Dow Jones Is Covering the U.S. Midterms